<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A variety of circumstantial evidence from humans has implicated the B cell antigen receptor (BCR) in the genesis of B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We generated mouse models designed to test this possibility directly, and we found that both the constitutive and antigen-stimulated state of a clonal BCR affected the rate and outcome of <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> initiated by the proto-oncogene MYC </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that arose in the presence of constitutive BCR differed from those initiated by MYC alone and resembled <z:hpo ids='HP_0011010'>chronic</z:hpo> B cell lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-CLL), whereas those that arose in response to antigen stimulation resembled large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, particularly Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>We linked the genesis of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> to antigen stimulus in three ways </plain></SENT>
<SENT sid="4" pm="."><plain>First, in reconstruction experiments, stimulation of B cells by an autoantigen in the presence of overexpressed MYC gave rise to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that were, in turn, dependent on both MYC and the antigen for survival and proliferation </plain></SENT>
<SENT sid="5" pm="."><plain>Second, genetic disruption of the pathway that mediates signaling from the BCR promptly killed cells of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> as well as the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> resembling B-CLL </plain></SENT>
<SENT sid="6" pm="."><plain>And third, growth of the murine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> could be inhibited by any of three distinctive <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi>, in accord with the dependence of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> on antigen-induced signaling </plain></SENT>
<SENT sid="7" pm="."><plain>Together, our results provide direct evidence that antigenic stimulation can participate in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e>, point to a potential role for the constitutive BCR as well, and sustain the view that the constitutive BCR gives rise to signals different from those elicited by antigen </plain></SENT>
<SENT sid="8" pm="."><plain>The mouse models described here should be useful in exploring further the pathogenesis of <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and in preclinical testing of new therapeutics </plain></SENT>
</text></document>